Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02791581 · ClinicalTrials.gov registry record · NA

Understanding and Predicting Breast Cancer Events After Treatment

A NA study of Breast Cancer, sponsored by Wake Forest University Health Sciences.

Active
Registry status
NA
Development phase
403
Enrollment target
20
Study locations

NCT02791581: Active NA study of Breast Cancer, sponsored by Wake Forest University Health Sciences.

NCT02791581 is a NA study of Breast Cancer that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 403 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02791581, a NA study of Breast Cancer, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
403 participants
Enrollment target
20
Study locations

Study Summary

This study is being done to see if patients receiving chemotherapy for breast cancer affects the heart, the ability to exercise and fatigue when compared to patients who do not have cancer.

Primary Outcome

Participants rate the degree to which each item applies in the past 7 days prior to Baseline using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Cardiac MRI

Study Locations (20)

Michigan

  • University of Michigan Comprehensive Cancer Center - Ann Arbor
  • Beaumont Hospital - Dearborn - Dearborn
  • Beaumont Hospital - Farmington Hills - Farmington Hills
  • Spectrum Health at Butterworth Campus - Grand Rapids
  • William Beaumont Hospital-Royal Oak - Royal Oak
  • William Beaumont Hospital - Troy - Troy

Indiana

  • IU Health North Hospital - Carmel
  • Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
  • Springmill Medical Center - Indianapolis

Minnesota

  • Saint John's Hospital - Healtheast - Maplewood
  • Abbott-Northwestern Hospital - Minneapolis
  • Health Partners Inc - Minneapolis

Florida

  • Moffitt Cancer Center - McKinley Campus - Tampa
  • Moffitt Cancer Center - Tampa

Kansas

  • University of Kansas Cancer Center - Kansas City
  • University of Kansas Hospital-Westwood Cancer Center - Westwood

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

District of Columbia

  • MedStar Washington Hospital Center - Washington D.C.

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 403 participants
Start Date 2017-07-21
Est. Completion 2034-07-31
Phase NA
Wake Forest University Health Sciences

1,140 total trials

What the registry record for NCT02791581 still lists

NCT02791581 is an interventional study that assigns participants to a tested intervention. The registered 403 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cardiac MRI is the first listed.

NCT02791581 names 20 study sites across 9 states, led by Michigan, Indiana, Minnesota.

Frequently Asked Questions

What is clinical trial NCT02791581 about?

NCT02791581 is a clinical study titled "Understanding and Predicting Breast Cancer Events After Treatment". This study is being done to see if patients receiving chemotherapy for breast cancer affects the heart, the ability to exercise and fatigue when compared to patients who do not have cancer.

What is the current status of trial NCT02791581?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 403 participants. The study started on 2017-07-21. Estimated completion is 2034-07-31.

What conditions does trial NCT02791581 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT02791581?

The interventions under investigation include: Cardiac MRI (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT02791581?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02791581 being conducted?

This trial has 20 study locations across Alabama, District of Columbia, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02791581's enrollment target sits among peer trials

403 229th of 1224 higher than 996 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05647122 · 403 participants · Phase 1

    First in Human Study of AZD9592 in Solid Tumors

  • NCT05674799 · 403 participants · NA

    NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks

  • NCT06244771 · 403 participants · Phase 1

    A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  • NCT05049057 · 404 participants · Phase 2

    Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02791581, the US trial registry maintained by the National Library of Medicine. NCT02791581 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.